Armata Pharmaceuticals IncNYSE American:ARMP
- LAST PRICE2.3899
- TODAY'S CHANGE (%)0.0999 (4.3624%)
- Bid / Lots2.3200/ 1
- Ask / Lots2.3500/ 1
- Open / Previous Close2.2800 / 2.2900
- Day Range
- 52 Week Range
- Volume2,904
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ARMP |
|---|---|---|
| 09:34 ET | 150 | 2.28 |
| 09:38 ET | 150 | 2.2096 |
| 12:16 ET | 1000 | 2.3881 |
| 12:18 ET | 1240 | 2.3899 |
Sep 5, 2024
Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, from 7:30AM ET on Thursday Sep 05, 2024 by Dow Jones
7:30AM ET on Thursday Sep 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Armata Pharmaceuticals Inc | 82.9M | -1.2x | --- |
Adlai Nortye Ltd | 72.7M | -0.3x | --- |
Beyondspring Inc | 82.6M | -5.2x | --- |
Coya Therapeutics Inc | 95.6M | -8.1x | --- |
Omega Therapeutics Inc | 69.5M | -0.9x | --- |
Vistagen Therapeutics Inc | 81.2M | -2.0x | --- |
Company Information
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Its two lead candidates addresses both chronic and acute bacterial infections. The Company's first lead candidate focused primarily on chronic bacterial infections is the clinical phage candidate for Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.
Contact Information
- Headquarters
- 5005 Mcconnell AveLOS ANGELES, CA, United States 90066
- Phone
- 310-665-2928
- Fax
- 310-665-2963
Executives
- Chief Executive Officer, Director
- Deborah Birx
- Principal Financial Officer, Senior Vice President - Finance
- David House
- Controller
- Richard Rychlik
- Independent Director
- Jules Haimovitz
- Independent Director
- Odysseas Kostas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $82.9M |
|---|---|
Revenue (TTM) | $3.7M |
Shares Outstanding | 36.2M |
Armata Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.81 |
EPS | $-1.95 |
Book Value | $-0.89 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 22.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,234.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
